5 research outputs found
Phase I study of continuous MKC-1 (cMKC-1) in patients (pts) with advanced or metastatic solid malignancies using a modified time-to-event continual reassessment method (TITE-CRM) for dose assignment.
Full text linkBreast cancer molecular subtypes and survival in a hospitalâbased sample in Puerto Rico
Full text linkA randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study
Full text link
